semaglutide approved for mash Semaglutide - Rezdiffra MASH Semaglutide Approved for MASH: A New Era in Liver Disease Treatment

Resmetirom The U.S. Food and Drug Administration (FDA) has granted accelerated approval to semaglutide, in the form of Wegovy 2Wegovy®is the first and only FDA-approvedonce-weekly GLP-1 RA medication to treat adults withMASHwith liver scarring,* along with a reduced calorie diet and ....4 mg injection, for the treatment of metabolic-associated steatohepatitis (MASH), also known as noncirrhotic MASH, with moderate to advanced liver fibrosis2025年8月20日—The FDA has granted acceleratedapprovalfor Wegovy for the treatment of noncirrhoticMASHwith moderate to advanced liver fibrosis in .... This landmark decision marks the first time a Glucagon-like peptide-1 (GLP-1) receptor agonist has been approved for this specific liver condition, heralding a significant advancement in MASH treatmentSemaglutide Gets FDA Greenlight for MASH. The approval is specifically for adults with MASH who exhibit liver scarring, excluding cases with cirrhosis作者：K Bowie·2025·被引用次数：6—2 The trial has reported thatsemaglutideled to improvements in liver scarring and a higher proportion of patients achieving resolution ofMASH....

Understanding MASH and Its Progression

MASH is a serious, progressive form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation and damage, often accompanied by fibrosis (scarring).2025年11月24日—Semaglutideis FDA-approved for MASH. Discover what it means for drug development and how Gubra's GAN DIO-MASHmodel leads preclinical ... If left untreated, MASH can advance to cirrhosis, liver failure, and increase the risk of liver cancer. The condition is closely linked to metabolic dysfunction, including obesity, type 2 diabetes, and dyslipidemia. Previously, treatment options for MASH were limited, often focusing on lifestyle modifications such as diet and exercise, and managing underlying metabolic conditions.2025年8月18日—Semaglutide(Wegovy) is the first GLP-1 receptor agonistapproved for MASHwith liver fibrosis, excluding cirrhosis cases. The phase 3 ESSENCE ...

The Efficacy of Semaglutide in Clinical Trials

The approval of semaglutide for MASH is supported by robust clinical trial data, notably the Phase 3 ESSENCE trialFDA Approval of Semaglutide for MASH Marks a Turning .... This pivotal study evaluated the efficacy and safety of semaglutide in adults with MASH and moderate to advanced liver fibrosis. The trial demonstrated that weekly semaglutide 2.4 mg led to significant improvements in histological features of MASH, including resolution of MASH and a reduction in liver scarring. A higher proportion of patients treated with semaglutide achieved resolution of MASH and improvement in fibrosis compared to placebo.

Specifically, the ESSENCE trial reported that semaglutide led to improvements in liver scarring and a higher proportion of patients achieving resolution of MASH as well as regression of fibrosis. The clinical trial exploring the use of semaglutide as a treatment for MASH tested a weekly 2.4 milligram (mg) doseAASLD Releases Updated Practice Guidance on .... This dosage is the same as that used for weight management in adults with obesity.

Wegovy: The First GLP-1 Receptor Agonist Approved for MASH

Wegovy (semaglutide) is now the first and only FDA-approved once-weekly GLP-1 RA medication indicated to treat adults with MASH and liver scarring, in conjunction with a reduced-calorie diet and exercise. This approval represents a significant milestone, offering a targeted therapeutic option for a condition that affects a substantial portion of the population. While other agents like Resmetirom and Rezdiffra have also received approval for MASH, Wegovy stands out as the first GLP-1 receptor agonist to gain this indication. It's important to note that semaglutide and Resmetirom are not approved for MASH cirrhosis, and thus should only be used among those with MASH without cirrhosis.Wegovy®is the first and only FDA-approvedonce-weekly GLP-1 RA medication to treat adults withMASHwith liver scarring,* along with a reduced calorie diet and ...

Expert Endorsement and Future Implications

Leading medical organizations, such as the American Association for the Study of Liver Diseases (AASLD), have applauded the FDA's approval of semaglutide for MASH.FDA Approves Treatment for Serious Liver Disease Known as ... This approval is seen as a turning point in liver care, providing a much-needed therapeutic option for patients suffering from this debilitating disease. The semaglutide FDA approved MASH treatment signifies a move towards more personalized and effective interventions for liver conditions. The use of semaglutide can lead to improved liver health outcomes and potentially reduce the progression to more severe liver diseases2025年8月15日—The U.S. Food and Drug Administration hasapprovedWegovy (semaglutide) injection to treat metabolic-associated steatohepatitis (MASH) in ....

The approval of semaglutide for MASH is based on improvement of MASH and fibrosis, granted under accelerated approval based on these key findings. This advancement is not only a victory for patients but also for ongoing research and drug development in the field of liver disease2025年8月20日—The FDA has granted acceleratedapprovalfor Wegovy for the treatment of noncirrhoticMASHwith moderate to advanced liver fibrosis in .... The successful application of semaglutide in preclinical mouse models, such as Gubra's GAN DIO-MASH model, further underscores its potential.

In conclusion, the FDA's approval of Wegovy (semaglutide) for MASH with liver fibrosis marks a new era in the management of this serious liver condition2025年9月15日—Novo Nordisk's Wegovy (semaglutide) has gained acceleratedapprovalfor treating metabolic dysfunction-associated steatohepatitis (MASH) .... This approved semaglutide MASH treatment offers hope and a tangible therapeutic path for millions of individuals affected by MASH worldwide.